Stocklytics Platform
Asset logo for symbol CADL
Candel Therapeutics
CADL
56
$6.72arrow_drop_down6.92%-$0.50
Penny Stock

Performance History

Chart placeholder
Key Stats
Open$7.16
Prev. Close$7.22
EPS-1.29
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap216921232.00
PE Ratio-
LOWHIGH
Day Range6.71
7.25
52 Week Range0.66
14.30
Ratios
P/B Ratio36.28
Revenue-
Operating M. %0.00%
Earnings$0.00
Earnings Growth %-101.87%
EBITDA Margin %-
ROE %-163.77%
EPS-1.29

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$891.46
Perf. (24h)
arrow_drop_up0.72%$6.45
Market Cap$834.88B
Price$489.53
Perf. (24h)
arrow_drop_up1.76%$8.48
Market Cap$451.06B
Price$145.64
Perf. (24h)
arrow_drop_down0.20%-$0.30
Market Cap$350.26B
Price$127.99
Perf. (24h)
arrow_drop_up0.38%$0.49
Market Cap$327.94B

About Candel Therapeutics (CADL)

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D.
Headquarters
Needham
Employees
76
Exchange
NASDAQ
add Candel Therapeutics to watchlist

Keep an eye on Candel Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Candel Therapeutics's (CADL) price per share?

The current price per share for Candel Therapeutics (CADL) is $6.72. The stock has seen a price change of -$0.5 recently, indicating a -6.93% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Candel Therapeutics (CADL)?

For Candel Therapeutics (CADL), the 52-week high is $14.3, which is 112.8% from the current price. The 52-week low is $0.66, the current price is 918.18% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Candel Therapeutics (CADL) a growth stock?

Candel Therapeutics (CADL) has shown an average price growth of 0.41% over the past three years. It has received a score of 96 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Candel Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Candel Therapeutics (CADL) stock price performance year to date (YTD)?

As of the latest data, Candel Therapeutics (CADL) has a year-to-date price change of 363.45%. Over the past month, the stock has experienced a price change of -43.91%. Over the last three months, the change has been 380%. Over the past six months, the figure is 474.36%.

help
Is Candel Therapeutics (CADL) a profitable company?

Candel Therapeutics (CADL) has a net income of -$37.94M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$38.39M. Furthermore, the EBITDA is -$35.68M.

help
What is the market capitalization of Candel Therapeutics (CADL)?

Candel Therapeutics (CADL) has a market capitalization of $204.13M. The average daily trading volume is 480.68K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level